SCHEMBL938422

SCHEMBL938422

NC(=O)N1CCCC2CCCCC21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ POLB P06746 2/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ DPP7 Q9UHL4 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ DRD4 P21917 1/20 0.42
▸ HSD11B1 P28845 7/20 0.41
▸ HSD17B1 P14061 1/20 0.40
▸ CNR2 P34972 1/20 0.39
▸ HTT P42858 1/20 0.37
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ F13A1 P00488 1/20 0.35
▸ TGM2 P21980 1/20 0.35
▸ TGM1 P22735 1/20 0.35
▸ SLC18A3 Q16572 1/20 0.34
▸ DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23842585 0.94 NPC1 (0.45) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL23842831 0.94 NPC1 (0.45) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL2125244 0.94 NPC1 (0.45) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL4449748 0.92 DPP7 (0.50) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL4449743 0.92 DPP7 (0.50) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL4397008 0.88 DPP7 (0.42) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL30291716 0.83 DPP4 (0.43) NPC1RAB9ASMN1; SMN2POLBHTT
SCHEMBL794610 0.83 NPC1 (0.53) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL770763 0.83 NPC1 (0.53) NPC1RAB9ASMN1; SMN2POLBTDP1
SCHEMBL2824467 0.81 NPC1 (0.56) NPC1RAB9ASMN1; SMN2POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4554569-A1 AGENT CONTAINING MALONIC ACID OR ITS DERIVATIVES FOR RESTORING METAL HOMEOSTASIS Oxford Antibiotic Group GmbH (AT) 2025-05-21 — — EP disclosed
WO-2024013400-A1 AGENT CONTAINING MALONIC ACID OR ITS DERIVATIVES FOR RESTORING METAL HOMEOSTASIS OXFORD ANTIBIOTIC GROUP GMBH (AT) 2024-01-18 — — WO disclosed
EP-4306107-A1 METAL HOMEOSTASIS RESTORATION AGENT Oxford Antibiotic Group GmbH (AT) 2024-01-17 — — EP disclosed
WO-2016199761-A1 DIFLUOROMETHYLENE COMPOUNDS 石原産業株式会社 2016-12-15 — — WO disclosed
EP-2283004-B1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE UNIV EDINBURGH (GB) 2015-05-27 — — EP disclosed
US-8614209-B2 Amido-thiophene compounds and their use THE UNIVERSITY OF EDINBURGH (GB) 2013-12-24 — — US disclosed
US-8362008-B2 Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors THE UNIVERSITY OF EDINBURGH (GB) 2013-01-29 — — US disclosed
US-20130012545-A1 Amido-Thiophene Compounds and Their Use THE UNIVERSITY OF EDINBURGH (GB) 2013-01-10 — — US disclosed
US-8299063-B2 Amido-thiophene compounds and their use THE UNIVERSITY OF EDINBURGH (GB) 2012-10-30 — — US disclosed
EP-2443113-A1 AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS THE UNIVERSITY OF EDINBURGH (GB) 2012-04-25 — — EP disclosed
WO-2010146338-A1 AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS THE UNIVERSITY OF EDINBURGH (GB) 2010-12-23 — — WO disclosed
US-20100267696-A1 Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors THE UNIVERSITY OF EDINBURGH 2010-10-21 — — US disclosed
EP-2229374-A1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS THE UNIVERSITY OF EDINBURGH (GB) 2010-09-22 — — EP disclosed
WO-2009112845-A1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE THE UNIVERSITY OF EDINBURGH (GB) 2009-09-17 — — WO disclosed
WO-2009074789-A1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS THE UNIVERSITY OF EDINBURGH (GB) 2009-06-18 — — WO disclosed
EP-0686698-B1 Biotechnological process for the production of cyclic S-alpha-aminocarboxylic acids and R-alpha-aminocarboxylic acid amides LONZA AG (CH) 2001-03-14 — — EP disclosed
US-5766893-A ENZYME CULTURE LONZA AG (CH) 1998-06-16 — — US disclosed
US-5622846-A RACEMIC MIXTURES OR OPTICALLY ACTIVE ISOMERS; MICROORGANISM WHICH USE THESE COMPOUNDS LONZA AG (CH) 1997-04-22 — — US disclosed
EP-0686698-A2 Biotechnological process for the production of cyclic S-alpha-aminocarboxylic acids and R-alpha-aminocarboxylic acid amides LONZA AG (CH) 1995-12-13 — — EP disclosed
WO-1993013066-A1 CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1993-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267696-A1 Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors HSD11B1, HSD11B2, HSD17B1 NPC1 204/4885RAB9A 2804/4885SMN1; SMN2 2427/4885
US-20130012545-A1 Amido-Thiophene Compounds and Their Use HSD11B1, HSD11B2, HSD17B1 NPC1 174/4885RAB9A 2460/4885SMN1; SMN2 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback